Partial ADAMTS13 deficiency in atypical hemolytic uremic syndrome

Blood

Volumn 122, Issue 8, 2013, Pages 1487-1493

  Feng, Shuju ^a   Eyler, Stephen J ^b   Zhang, Yuzhou ^b   Maga, Tara ^b   Nester, Carla M ^b   Kroll, Michael H ^a   Smith, Richard J ^b   Afshar Kharghan, Vahid ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT FACTOR H; DNA; FIBRINOGEN; THROMBOMODULIN; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; ADAM PROTEIN; ADAMTS13 PROTEIN, HUMAN; AUTOANTIBODY; HYBRID PROTEIN;

AMINO ACID SUBSTITUTION; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; ENZYME ACTIVITY; GENE FREQUENCY; GENE MUTATION; GENETIC SCREENING; GENETIC VARIATION; HEMOLYTIC UREMIC SYNDROME; HUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; ADOLESCENT; ADULT; ALLELE; BLOOD; CHILD; FEMALE; GENETIC POLYMORPHISM; GENETICS; IMMUNOLOGY; INFANT; MALE; METABOLISM; MUTATION; PRESCHOOL CHILD;

ADAM PROTEINS; ADOLESCENT; ADULT; ALLELES; AUTOANTIBODIES; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; COMPLEMENT FACTOR H; DNA; FEMALE; HEMOLYTIC-UREMIC SYNDROME; HUMANS; INFANT; MALE; MUTATION; POLYMORPHISM, GENETIC; RECOMBINANT FUSION PROTEINS; YOUNG ADULT;

EID: 84886851977     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-03-492421     Document Type: Article

References (25)

1. Remuzzi G, Galbusera M, Noris M, et al; Italian Registry of Recurrent and Familial HUS/TTP. Thrombotic thrombocytopenic purpura/ hemolytic uremic syndrome. von Willebrand factor cleaving protease (ADAMTS13) is deficient in recurrent and familial thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Blood. 2002;100(3): 778-785.
2. Sethi S, Sukov WR, Zhang Y, et al. Dense deposit disease associated with monoclonal gammopathy of undetermined significance. Am J Kidney Dis. 2010;56(5):977-982.
3. Goicoechea de Jorge E, Harris CL, Esparza-Gordillo J, et al. Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome. Proc Natl Acad Sci USA. 2007;104(1):240-245.
4. Tao Z, Anthony K, Peng Y, et al. Novel ADAMTS-13 mutations in an adult with delayed onset thrombotic thrombocytopenic purpura. J Thromb Haemost. 2006;4(9):1931-1935.
5. Camilleri RS, Cohen H, Mackie IJ, et al. Prevalence of the ADAMTS-13 missense mutation R1060W in late onset adult thrombotic thrombocytopenic purpura. J Thromb Haemost. 2008;6(2):331-338.
6. Noris M, Bucchioni S, Galbusera M, et al; International Registry of Recurrent and Familial HUS/TTP. Complement factor H mutation in familial thrombotic thrombocytopenic purpura with ADAMTS13 deficiency and renal involvement. J Am Soc Nephrol. 2005;16(5):1177-1183.
7. Furlan M, Robles R, Galbusera M, et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med. 1998;339(22): 1578-1584.
8. Veyradier A, Obert B, Haddad E, et al. Severe deficiency of the specific von Willebrand factor-cleaving protease (ADAMTS 13) activity in a subgroup of children with atypical hemolytic uremic syndrome. J Pediatr. 2003;142(3): 310-317.
9. Ono T, Mimuro J, Madoiwa S, et al. Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: its correlation with development of renal failure. Blood. 2006; 107(2):528-534.
10. Nguyen TC, Liu A, Liu L, et al. Acquired ADAMTS-13 deficiency in pediatric patients with severe sepsis. Haematologica. 2007;92(1):121-124.
11. Lattuada A, Rossi E, Calzarossa C, Candolfi R, Mannucci PM. Mild to moderate reduction of a von Willebrand factor cleaving protease (ADAMTS-13) in pregnant women with HELLP microangiopathic syndrome. Haematologica. 2003;88(9):1029-1034.
12. Kokame K, Nobe Y, Kokubo Y, Okayama A, Miyata T. FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol. 2005;129(1):93-100.
13. Cruz MA, Whitelock J, Dong JF. Evaluation of ADAMTS-13 activity in plasma using recombinant von Willebrand Factor A2 domain polypeptide as substrate. Thromb Haemost. 2003;90(6): 1204-1209.
14. Studt JD, Böhm M, Budde U, Girma JP, Varadi K, Lämmle B. Measurement of von Willebrand factor-cleaving protease (ADAMTS-13) activity in plasma: a multicenter comparison of different assay methods. J Thromb Haemost. 2003;1(9): 1882-1887.
15. Tripodi A, Chantarangkul V, Böhm M, et al. Measurement of von Willebrand factor cleaving protease (ADAMTS-13): results of an international collaborative study involving 11 methods testing the same set of coded plasmas. J Thromb Haemost. 2004;2(9):1601-1609.
16. Zhou Z, Han H, Cruz MA, López JA, Dong JF, Guchhait P. Haemoglobin blocks von Willebrand factor proteolysis by ADAMTS-13: a mechanism associated with sickle cell disease. Thromb Haemost. 2009;101(6):1070-1077.
17. Loirat C, Frémeaux-Bacchi V. Atypical hemolytic uremic syndrome. Orphanet J Rare Dis. 2011; 6:60.
18. Kokame K, Matsumoto M, Soejima K, et al. Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity. Proc Natl Acad Sci USA. 2002;99(18):11902-11907.
19. Akiyama M, Kokame K, Miyata T. ADAMTS13 P475S polymorphism causes a lowered enzymatic activity and urea lability in vitro. J Thromb Haemost. 2008;6(10):1830-1832.
20. Jang MJ, Kim NK, Chong SY, Kim HJ, Lee SJ, Kang MS, Oh D. Frequency of Pro475Ser polymorphism of ADAMTS13 gene and its association with ADAMTS-13 activity in the Korean population. Yonsei Med J. 2008;49(3): 405-408.
21. Ruan C, Dai L, Su J, Wang Z, Ruan C. The frequency of P475S polymorphism in von Willebrand factor-cleaving protease in the Chinese population and its relevance to arterial thrombotic disorders. Thromb Haemost. 2004; 91(6):1257-1258.
22. Bongers TN, De Maat MP, Dippel DW, Uitterlinden AG, Leebeek FW. Absence of Pro475Ser polymorphism in ADAMTS-13 in Caucasians. J Thromb Haemost. 2005;3(4):805.
23. Plaimauer B, Fuhrmann J, Mohr G, et al. Modulation of ADAMTS13 secretion and specific activity by a combination of common amino acid polymorphisms and a missense mutation. Blood. 2006;107(1):118-125.
24. Schettert IT, Pereira AC, Lopes NH, Hueb WA, Krieger JE. Association between ADAMTS13 polymorphisms and risk of cardiovascular events in chronic coronary disease. Thromb Res. 2010; 125(1):61-66.
25. Kavanagh D, Goodship T. Genetics and complement in atypical HUS. Pediatr Nephrol. 2010;25(12):2431-2442.